Imatinib Amarox

Imatinib, the active ingredient in Imatinib Amarox, is a tyrosine kinase inhibitor presented as an oral tablet for systemic use. It targets specific cancers such as chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution and ensures regulatory compliance throughout the supply chain.

Imatinib is indicated for malignancies driven by BCR‑ABL, c‑KIT or PDGFR signaling pathways.

Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission and prolongs disease‑free intervals. Gastrointestinal stromal tumor (GIST): inhibits tumor growth and reduces recurrence risk.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially around ankles. - Fatigue: generalized tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced heart function, may present with dyspnea.

When prescribing Imatinib, clinicians should observe several safety measures to minimize risk.

- Monitor blood counts: perform regular complete blood count assessments. - Assess liver function: check hepatic enzymes before and during therapy. - Evaluate cardiac status: perform baseline and periodic cardiac evaluations. - Pregnancy considerations: avoid use in pregnancy unless benefits outweigh unknown risks. - Review concomitant medications: assess for potential drug interactions before initiation. - Store below 25°C: keep in the original container, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels and risk toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower imatinib exposure and reduce efficacy. - Antacids containing aluminum or magnesium: can reduce oral absorption of imatinib.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly increase drug levels. - Warfarin: imatinib may enhance anticoagulant effect, requiring INR monitoring. - Diuretics (e.g., furosemide): may increase risk of fluid retention and edema.